ARTICLE | Clinical News
Capesaris: Phase II hold
February 27, 2012 8:00 AM UTC
GTx Inc. (NASDAQ:GTXI), Memphis, Tenn. Product: Capesaris ( GTx-758) Business: Cancer Molecular target: Estrogen receptor alpha Description: Oral selective estrogen receptor alpha agonist Indication...